The GLOVe regimen, combining glofitamab, lenalidomide, and venetoclax, shows rapid and deep responses in high-risk MCL patients with manageable toxicity. All evaluable patients achieved complete ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback